ROCKET PHARMACEUTICALS, INC. RCKT
We are a fully integrated, late-stage biotechnology company focused on the development, manufacturing, and potential commercialization of genetic therapies for rare and often fatal diseases with high unmet medical need. Our innovative multi-platform approach is designed to create best-in-class gene therapy product candidates aimed at correcting the underlying genetic causes of complex inherited cardiomyopathies and related disorders, with the potential to deliver transformative and durable clinical benefits. Our platform is supported by in-house research and development capabilities and current cGMP manufacturing facilities that enable end-to-end control of clinical production, process development, and scale-up for potential commercialization.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M | $105.4M | $57.9M | $53.3M | $14.9M | $6.0M |
| SG&A | $86.5M | $102.0M | $73.3M | $58.8M | $41.8M | $28.9M | $18.2M | $17.9M | $4.9M | $1.6M |
| Total operating expenses | $231.7M | $273.2M | $259.7M | $224.3M | $167.2M | $134.3M | $76.2M | $71.2M | $19.8M | $7.6M |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M | -$134.3M | -$76.2M | -$71.2M | -$19.8M | -$7.6M |
| Interest expense | $1.9M | $1.9M | $1.9M | $1.9M | $3.0M | $7.0M | $6.0M | $6.0M | $0 | $0 |
| Pre-tax income | -$223.1M | -$258.7M | -$245.6M | — | — | — | — | — | — | — |
| Income tax | $0 | $0 | $0 | — | — | — | — | — | — | — |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M | -$139.7M | -$77.3M | -$74.5M | -$19.6M | -$7.6M |
| EPS, basic | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 | — | — | — |
| EPS, diluted | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 | -1.89 | -2.88 | -1.11 |
| Shares, diluted (wtd. avg.) | $111.1M | $94.8M | $84.0M | $68.1M | $63.2M | $55.4M | $49.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $77.6M | $163.6M | $57.3M | $141.9M | $234.0M | $298.7M | $186.9M | $112.8M | $18.3M | $9.7M |
| Short-term investments | $111.4M | $208.7M | $317.3M | $215.9M | $156.0M | $185.6M | $118.7M | $94.4M | $0 | $96.7M |
| Total current assets | $192.7M | $378.2M | $378.2M | $364.1M | $392.1M | $487.3M | $307.8M | $209.1M | $19.0M | $128.3M |
| Property, plant and equipment | $28.2M | $36.8M | $39.2M | $29.0M | $22.3M | $19.2M | $29.5M | $2.0M | $985.0K | $1.1M |
| Goodwill | $39.2M | $39.2M | $39.2M | $39.2M | $30.8M | $30.8M | $30.8M | $30.8M | $0 | — |
| Other intangibles | $25.1M | $25.1M | $25.1M | $25.7M | $0 | — | — | — | — | — |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M | $590.8M | $372.1M | $251.3M | $20.1M | $129.6M |
| Accounts payable | $27.3M | $37.8M | $45.8M | $36.7M | $19.6M | $25.5M | $17.4M | $15.4M | $4.5M | $1.6M |
| Total current liabilities | $30.2M | $40.7M | $48.5M | $39.2M | $22.2M | $32.6M | $18.3M | $15.4M | $4.5M | $7.0M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M | $87.3M | $64.8M | $57.3M | $4.6M | $56.5M |
| Retained earnings | -$1.44B | -$1.22B | -$959.4M | -$713.8M | -$491.9M | -$322.8M | -$183.1M | -$105.9M | -$31.4M | -$238.9M |
| Total equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M | $503.5M | $307.3M | $194.0M | $15.5M | $8.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M | -$74.6M | -$64.7M | -$53.8M | -$16.0M | -$5.5M |
| Depreciation and amortisation | $8.9M | $7.2M | $4.9M | $3.9M | $3.2M | $1.1M | $426.0K | $330.0K | $204.0K | $67.0K |
| Stock-based compensation | $37.1M | $43.9M | $39.4M | $31.0M | $29.2M | $18.6M | $13.4M | $13.6M | $1.3M | $274.0K |
| Capital expenditure | $440.0K | $5.9M | $16.4M | $8.4M | $7.6M | $20.6M | $23.3M | $1.5M | $760.0K | $335.0K |
| Investing cash flow | $103.8M | $131.7M | -$98.1M | -$69.3M | $18.9M | -$96.6M | -$39.0M | -$5.3M | -$760.0K | -$335.0K |
| Financing cash flow | $148.0K | $185.7M | $208.4M | $155.3M | $37.7M | $283.0M | $177.8M | $153.5M | $25.4M | $16.0K |
| Buybacks | — | — | — | $47.0K | $0 | $72.0K | $0 | $0 | $0 | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-013335.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |